Showing results (1361-1370 of 4,517) with videos related to

Sort By:
Pageof 452
Future Oncology (London, England)|August 10, 2018
Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life studyRodolfo Sacco, Alessandro Granito, Irene Bargellini, et al.
Future Oncology (London, England)|July 19, 2018
Tailoring breast cancer therapies to reduce mortality and improve quality of life: San Antonio Breast Cancer Symposium 2017 (part 1)John R Benson, Ismail Jatoi
Future Oncology (London, England)|July 19, 2018
miRNA in a multiomic context for diagnosis, treatment monitoring and personalized management of metastatic breast cancerPavol Zubor, Peter Kubatka, Zuzana Dankova, et al.
Future Oncology (London, England)|July 19, 2018
Analysis of risk factors of lymph node metastasis in rectal neuroendocrine neoplasms using multicenter dataGengzhou Wei, Xingyu Feng, Wei Wang, et al.
Future Oncology (London, England)|July 31, 2018
The role of carfilzomib in treatment of newly diagnosed multiple myelomaSusanne Strifler, Stefan Knop
Future Oncology (London, England)|August 8, 2018
Changing pattern of secondary cancers among patients with malignant thymoma in the USAVivek Kumar, Mohit Garg, Abhishek Goyal, et al.
Future Oncology (London, England)|October 25, 2021
Additional adjuvant capecitabine in early breast cancer patients: a meta-analysis of randomized controlled trialsWenqi Zhou, Yong Cao, Ping Gou, et al.
Future Oncology (London, England)|October 19, 2021
VGH-TAYLOR: Comprehensive precision medicine study protocol on the heterogeneity of Taiwanese breast cancer patientsChun-Yu Liu, Chi-Cheng Huang, Yi-Fang Tsai, et al.
Future Oncology (London, England)|October 12, 2021
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancerCiara C O'Sullivan, Karla V Ballman, Linda McCall, et al.
Future Oncology (London, England)|October 13, 2021
GALNT14 regulates ferroptosis and apoptosis of ovarian cancer through the EGFR/mTOR pathwayHua-Wen Li, Mu-Biao Liu, Xue Jiang, et al.
Pageof 452